Bartlomiej Borek

This inventor holds 9 USPTO granted patents and 1 published patent application and 3 EPO patents. Top assignees: Oncoarendi Therapeutics S.a., Molecure S.a.. Active years: 2018-2026.

USPTO Granted Patents = 9 (Patent Applications = 1)

% Patents Active = 88.9

EPO Patents = 3 (Patent Applications = 5)

Average Co-Inventor Count = 11.1

ph-index = 3

Forward Citations = 18(Granted Patents)

Location History:

Łódź, PL (2018 - 2019)
Lodz, PL (2019 - 2024)

Company Filing History:

7 out of 8

Oncoarendi Therapeutics S.a.

Years Active: 2018-2026

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12612420 - Arginase inhibitors and methods of use thereof (2026-04-28),

2. 12404279 - Deubiquitinase inhibitors and methods of use thereof (2025-09-02),

3. 12053451 - Arginase inhibitors and their therapeutic applications (2024-08-06),

4. 10912755 - Arginase inhibitors and their therapeutic applications (2021-02-09),

5. 10851099 - Dipeptide piperidine derivatives (2020-12-01),

6. 10538508 - Substituted amino triazoles useful as human chitinase inhibitors (2020-01-21),

7. 10391077 - Arginase inhibitors and their therapeutic applications (2019-08-27),

8. 10208020 - Substituted amino triazoles useful as human chitinase inhibitors (2019-02-19),

9. 9944624 - Substituted amino triazoles useful as human chitinase inhibitors (2018-04-17),

Title: Bartlomiej Borek: Innovator in Therapeutic Compounds

Introduction

Bartlomiej Borek is a prominent inventor based in Lodz, Poland. He has made significant contributions to the field of therapeutic compounds, particularly in the development of inhibitors that target specific enzymatic activities. With a total of 9 patents, Borek's work is paving the way for new treatments in various medical conditions.

Latest Patents

Borek's latest patents include innovative compounds such as deubiquitinase inhibitors and methods of use thereof. These compounds are small molecule therapeutics that serve as potent inhibitors of USP7 activity. The invention also encompasses pharmaceutical compositions that include these compounds, along with methods for their application in treating or preventing diseases associated with USP7 activity. Another notable patent involves arginase inhibitors and their therapeutic applications. This patent discloses small molecule therapeutic compounds that effectively inhibit arginase 1 and arginase 2 activity. Additionally, it provides pharmaceutical compositions and methods for using these compounds to treat or prevent conditions related to arginase activity.

Career Highlights

Throughout his career, Borek has worked with various companies, including Oncoarendi Therapeutics S.A. and Molecure S.A. His expertise in the field has allowed him to contribute to the advancement of therapeutic solutions that address critical health issues.

Collaborations

Borek has collaborated with notable professionals in his field, including Adam A. Golebiowski and Jacek P. Olczak. These collaborations have further enriched his research and development efforts.

Conclusion

Bartlomiej Borek's innovative work in therapeutic compounds highlights his role as a key inventor in the medical field. His patents and collaborations reflect a commitment to advancing healthcare solutions.